Plans to build a long-promised biological manufacturing facility in Manhattan have fizzled, though company leaders prefer not ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

New York, New York--(Newsfile Corp. - January 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ ...